• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA committee supports Nordisk’s cardiovascular risk claim for Victoza label

June 22, 2017 By Sarah Faulkner

Novo NordiskNovo Nordisk (NYSE:NVO) shares ticked up 1% earlier this week after an advisory committee for the FDA voted to recommend that the company’s cardiovascular risk reduction claim be added to its Victoza (liraglutide) label.

The discussions among committee members involved data from the 9,300-patient Leader trial, which involved people with Type II diabetes at high risk of major cardiovascular events.

Nordisk first submitted the supplemental new drug application to the FDA in October last year. The company said it expects feedback from the regulatory watchdog in the 3rd quarter of this year.

The advisory committee voted unanimously, 19-0, in support of the claim that liraglutide is not associated with unacceptably high cardiovascular risk. On the claim that the company provided enough evidence to show that Victoza reduces cardiovascular risk, the committee voted 17-2.

“Cardiovascular disease is the number 1 cause of death for people with Type II diabetes, and today’s discussion is an important reminder that there is an unmet need to provide benefits beyond HbA1C control in this population,” Todd Hobbs, Nordisk’s VP & U.S. chief medical officer, said in prepared remarks. “The positive vote from EMDAC puts us 1 step closer to expanding our offering to reduce the risk of cardiovascular events in people with Type II diabetes.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news

Filed Under: Cardiovascular, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS